MINNEAPOLIS, Aug. 1, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the fiscal 2014 first quarter ended June 30, 2013.
Fiscal First Quarter 2014 Financial ResultsFiscal first quarter 2014 sales in the U.S. increased 6%, driven by a 10% increase in sales of the Urgent® PC Neuromodulation System, compared with fiscal first quarter a year ago. U.S. Urgent PC Sales in the fiscal first quarter of 2014 were $2.8 million. Global sales increased 5% to $5.8 million in the first quarter of fiscal 2014, compared with $5.6 million in the fiscal first quarter a year ago.
"Fiscal first quarter sales of Urgent PC grew 11% from the fourth quarter of fiscal 2013, despite the distractions we faced. This was the first sequential quarterly growth we've achieved in three quarters and is a strong indication that the changes we have made in the sales organization are beginning to gain traction," said Rob Kill, President and Chief Executive Officer of Uroplasty. "As we look ahead into the new fiscal year, we are optimistic about the outlook. We have innovative and effective product lines combined with favorable reimbursement that continues to improve. The market is large and remains underpenetrated. With the resolution of our leadership and fiscal 2013 financial statements, we are fully focused on growing sales and driving to profitability as we seek to enhance value for our investors."
Net sales to customers outside the U.S. for the fiscal first quarter totaled $1.6 million, compared to $1.5 million in the fiscal first quarter last year. Excluding the impact of fluctuations in foreign currency exchange rates, sales outside the U.S. were down 3%.
The Company reported a gross margin of 87.2% in the recent fiscal first quarter compared with 86.5% in the same quarter a year ago. The operating loss of $1.6 million in the fiscal first quarter compares with a $1.0 million operating loss in the same quarter last year. Excluding non-cash charges for share-based compensation and depreciation and amortization expense, the non-GAAP operating loss was $1.5 million in the first quarter of fiscal 2014, compared with a $567,000 non-GAAP operating loss in the first quarter a year ago. The increase in operating loss was primarily attributable to an increase in operating expenses.
Novitas Solutions, Inc. Expands Coverage of PTNSUroplasty also announced that, effective today, August 1, 2013, Novitas Solutions, Inc. has expanded coverage for Posterior Tibial Nerve Stimulation (PTNS) using Urgent PC for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence. This increased coverage includes additional diagnostic codes as well as expansion of on-going therapy from 12 months to up to two years.
Novitas Solutions, Inc., a Medicare Administrative Contractor, provides medical and drug benefits to approximately 11 million Medicare beneficiaries in the states of Arkansas, Colorado, Delaware, District of Columbia, Louisiana, Maryland, Mississippi, New Jersey, New Mexico, Oklahoma, Pennsylvania and Texas. Novitas has expanded patient access to PTNS by adding diagnosis codes that include frequency, urgency and urge incontinence, the hallmark symptoms of overactive bladder. Uroplasty estimates that PTNS coverage today has been extended to a total of approximately 140 million private coverage and Medicare beneficiaries.
Conference CallUroplasty will host a conference call and webcast today at 3:30 pm Central, 4:30 pm Eastern, to review the financial results for the fiscal first quarter of 2014. Rob Kill, President and Chief Executive Officer, will host. Individuals wishing to participate in the conference call should dial 877-941-2333. No passcode is necessary. An audio replay will be available for 30 days following the call at 800-406-7325 with the passcode 4632547#.
To access a live webcast of the call, go to Uroplasty's website at www.uroplasty.com and click on the Investor Relations section. An archived webcast will also be available at investor.uroplasty.com
About Uroplasty, Inc. Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.
Forward-Looking InformationThis press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC. In particular, we cannot be certain that we will ever achieve sustained profitability, that the rate of reimbursement for PTNS treatments will be adequate to justify the cost of our product, that other Medicare carriers or private payers will provide coverage for this treatment or that existing carriers and payers will not change their coverage decisions, that the rate of adoption of our products by new customers will continue, or that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.
For Further Information:
Rob Kill, President and CEO
Jenifer Kirtland (Investors)
Chris Gale (Media)
UROPLASTY, INC. AND SUBSIDIARIESCONDENSED Consolidated Statements of Operations(Unaudited)Three Months EndedJune 30,20132012Net sales
$5,840,841$5,577,123Cost of goods sold
5,092,7944,821,536Operating expensesGeneral and administrative
1,580,7631,091,846Research and development
479,660563,041Selling and marketing
(1,601,686)(1,013,795)Other income (expense)Interest income
9,26412,578Foreign currency exchange (loss) gain
(2,695)(9,671)6,5692,907Loss before income taxes
(1,595,117)(1,010,888)Income tax expense
$(1,609,292)$(1,019,355)Basic and diluted loss per common share
$(0.08)$(0.05)Weighted average common shares outstanding:Basic and diluted
UROPLASTY, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(Unaudited)June 30, 2013March 31, 2013AssetsCurrent assets:Cash and cash equivalents & short-term investments
$13,659,835$11,470,469Accounts receivable, net
544,017566,536Total current assets
17,385,27515,309,385Property, plant, and equipment, net
1,151,2181,033,085Intangible assets, net
399,6723,451,711Deferred tax assets
$19,175,950$20,040,735Liabilities and Shareholders' EquityCurrent liabilities:Accounts payable
$883,827$618,916Current portion – deferred rent
30,87835,000Income tax payable
868,938476,287Total current liabilities
3,355,8332,688,778Deferred rent – less current portion
05,141Accrued pension liability
4,065,8263,354,499Total shareholders' equity
15,110,12416,686,236Total liabilities and shareholders' equity
UROPLASTY, INC. AND SUBSIDIARIESCONDENSED Consolidated Statements of Cash Flows (Unaudited)Three Months EndedJune 3020132012Cash flows from operating activities:Net loss
$ (1,609,292)$ (1,019,355)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization
87,013288,548Loss on disposal of equipment
(5,881)599Amortization of premium on marketable securities
3,3428,091Share-based consulting expense
01,623Share-based compensation expense
16,044162,435Deferred income tax expense (benefit)
2,178(1,117)Deferred rent credit
(9,263)(9,111)Changes in operating assets and liabilities:Accounts receivable, net
39,773(122,672)Other current assets
383,43696,108Accrued pension liability, net
40,07341,029Net cash used in operating activities
(685,094)(701,701)Cash flows from investing activities:Proceeds from maturity of available-for-sale investments
1,000,000-Proceeds from maturity of held-to-maturity investments
820,0003,320,000Purchases of available-for-sale investments
-(3,218,286)Purchases of property, plant and equipment
(189,789)(73,902)Proceeds from sale of property, plant and equipment
6,080-Purchases of intangible assets
-(4,440)Net cash provided by investing activities
1,636,29123,372Cash flows from financing activities:Net cash provided by financing activities
--Effect of exchange rate changes on cash and cash equivalents
9,312(18,642)Net decrease in cash and cash equivalents
960,509(696,971)Cash and cash equivalents at beginning of period
3,533,8644,653,226Cash and cash equivalents at end of period
$4,494,373$3,956,255Cash paid during the period for income taxes
Non-GAAP Financial Measures: The following table reconciles our operating loss calculated in accordance with accounting principles generally accepted in the U.S. (GAAP) to non-GAAP financial measures that exclude non-cash charges for share-based compensation, and depreciation and amortization expenses from gross profit, operating expenses and operating loss. The non-GAAP financial measures used by management and disclosed by us are not a substitute for, or superior to, financial measures and consolidated financial results calculated in accordance with GAAP, and you should carefully evaluate our reconciliations to non-GAAP. We may calculate our non-GAAP financial measures differently from similarly titled measures used by other companies. Therefore, our non-GAAP financial measures may not be comparable to those used by other companies. We have described the reconciliations of each of our non-GAAP financial measures described above to the most directly comparable GAAP financial measures.
We use these Non-GAAP financial measures, and in particular non-GAAP operating loss, for internal managerial purposes because we believe such measures are one important indicator of the strength and the operating performance of our business. Analysts and investors frequently ask us for this information. We believe that they use these measures to evaluate the overall operating performance of companies in our industry, including as a means of comparing period-to-period results and as a means of evaluating our results with those of other companies.
Our non-GAAP operating loss during the three months ended June 30, 2013 and 2012 was approximately $1.5 million and $561,000, respectively. The increase in non-GAAP operating loss for the three months ended June 30, 2013 over the corresponding period a year ago is attributed to the increase in operating spending, offset slightly by the increase in net sales and gross profit percent.
Expense AdjustmentsThree-Months EndedGAAPShare-based ExpenseDepreciationAmortization of IntangiblesNon-GAAP30-Jun-13Gross Profit
$5,110,000% of net sales
87.2%87.5%Operating ExpensesGeneral and administrative
1,609,000Research and development
465,000Selling and marketing
$4,837,000% of net sales
86.5%86.7%Operating ExpensesGeneral and administrative
959,000Research and development
550,000Selling and marketing
|SOURCE Uroplasty, Inc.|
Copyright©2012 PR Newswire.
All rights reserved